Efficacy and safety of pathogen‐reduced platelet concentrates in children with cancer: a retrospective cohort study

Abstract

In spite of lower numerical increase in PLT count, the hemostatic efficacy and safety of PR PLT transfusions was comparable with the control group. Adverse event rates did not differ between groups, but the sample size was relatively small.

Use and safety of riboflavin and UV light‐treated platelet transfusions in children over a five‐year period: focusing on neonates

“…Our comparative study shows that neonates transfused with PLTs diluted in PAS and treated with riboflavin and UV light‐PRT require the transfusion of more PLTs than neonates receiving standard PLTs. Additionally, the adverse transfusion reaction rate in children transfused with PAS‐PLTs treated with riboflavin and UV light was found to be in accordance with data in the literature for children and adults receiving PLTs treated with the same PRT. PRT‐treated PLTs seem to be safe for children, since in 5 years (2013‐2017) not a single severe PLT transfusion reaction was reported in children transfused with riboflavin and UV light‐treated PLTs.…”

“…The only previous report describing the use of such PRT‐treated‐PLTs in children included only 51 pediatric patients (age range: 0.4‐18 years; mean: 11 years) transfused with 141 riboflavin and UV light treated‐PLTs and 86 controls (age range: 0.4‐18 years; mean 11 years) transfused with 291 standard PLTs. These authors found that the CCI at 1 to 4 hours and at 18 to 24 hours were significantly higher in the control group, although both groups reached clinically effective CCI …”

“…Additionally, a retrospective study on the efficacy and safety of riboflavin and UV light‐PRT‐treated PLTs in pediatric cancer patients found a low rate of transfusion‐related adverse events that was not significantly different from the control group transfused with non‐PRT‐treated PLT . Therefore, riboflavin and UV light PRT together with PLT storage in PAS can apparently reduce the rate of febrile and allergic reactions to PLT transfusions in children.…”

“…Since 2013, the Balearic Islands Blood Bank (BIBB) has been using riboflavin and UV light‐treated PLTs in transfusion support for adult and pediatric patients with thrombocytopenia. Currently, there are very few published reports on PRT based on riboflavin and UV light for PLT transfusion in the pediatric population . With the aim of shedding some light on this field, a two‐part study was conducted: 1) a study investigating the safety of riboflavin and UV light‐treated PLT transfusions in children compared with adults over a 5‐year period (2013‐2017); 2) an observational study in neonates evaluating the transfusion efficacy of riboflavin and UV light‐treated PLTs compared with standard PLTs over two 5‐year periods (2003‐2007 vs. 2013‐2017).…”

Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low‐resource settings

“…Limited data suggest that Mirasol ® ‐treated platelets have comparable hemostatic efficacy to untreated (i.e. standard) platelets . A single‐blind, randomized, clinical trial ( n = 24 healthy, adult volunteers) comparing red‐blood‐cell (RBC) components prepared from Mirasol ® ‐treated versus untreated whole blood showed that the Mirasol ® ‐treated whole blood‐derived RBCs met FDA acceptability criteria for red cell recovery (82·5 ± 3·9% [of the pre‐PR count] vs. 91·7 ± 6·8% in treated and control groups, respectively).…”